POTÁČOVÁ, Anna, Jana ČUMOVÁ, Irena KASALOVÁ, Ondrej ŠEDO, Zbyněk ZDRÁHAL and Roman HÁJEK. The effect of bortezomib on myeloma cell line. In XII. International Myeloma Workshop. 2009. ISBN 1557-9190.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name The effect of bortezomib on myeloma cell line
Name in Czech Vliv bortezomibu na myelomové buňky
Authors POTÁČOVÁ, Anna, Jana ČUMOVÁ, Irena KASALOVÁ, Ondrej ŠEDO, Zbyněk ZDRÁHAL and Roman HÁJEK.
Edition XII. International Myeloma Workshop, 2009.
Other information
Original language English
Type of outcome Conference abstract
Field of Study 30200 3.2 Clinical medicine
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
Organization unit Faculty of Science
ISBN 1557-9190
UT WoS 000268206500217
Keywords (in Czech) mnohočetný myelom;bortezomib
Keywords in English multiple myeloma; proteomics;bortezomib
Tags bortezomib, multiple myeloma, proteomics
Changed by Changed by: Mgr. Anna Potáčová, Ph.D., učo 44190. Changed: 13/3/2009 14:51.
Abstract
Introduction: Multiple myeloma (MM) is still an incurable disease characterized by the clonal expansion of malignant plasma cells. New anticancer drugs further improve prognosis of myeloma patients. The aim of this study was to evaluate changes in protein expression of myeloma cell line ARH 77 after bortezomib treatment. Materials and methods: Myeloma cell line ARH 77 was treated with bortezomib (10 – 40nM) for various periods of time (24 and 48 hours). The proteins contained in total myeloma cell lysate were separated by 2-dimensional polyacrylamide gel electrophoresis (2D-PAGE) and the differentially expressed proteins between the untreated and treated cell lines were excised and identified by mass spectrometry. Results: There were analyzed 94 proteins differentially expressed between treated and control cells; total of 34 protein spots were upregulated: proteins involved in regulation of apoptosis, chaperons/stress related proteins, proteolysis of ubiquitin/protein degradation and cytoskeleton proteins. Sixty protein spots were downregulated: proteins involved in synthesis, regulation of apoptosis, chaperons/stress related proteins, regulation of cell cycle proteins, proteins connected to glycolysis and proteolysis of ubiquitin/protein degradation and antioxidant/redox proteins. Conclusion: We identified 94 proteins altered in myeloma cells after various exposure of to bortezomib. This proteomic approach can contribute to elucidation of mechanisms of new anticancer drugs action.
Links
LC06027, research and development projectName: Univerzitní výzkumné centrum - Česká myelomová skupina (Acronym: LC MGUS)
Investor: Ministry of Education, Youth and Sports of the CR, University Research Centre - Czech Myeloma Group
MSM0021622434, plan (intention)Name: Od klasických prognostických markerů ke klinicky aplikovatelným farmakogenomickým a farmakoproteomickým projektům u mnohočetného myelomu a monoklonálních gamapatií
Investor: Ministry of Education, Youth and Sports of the CR, From classic prognostic markers to clinical applications in selected pharmacogenomic and pharmacoproteomic projects in multiple myeloma and monoclonal gammapathies
PrintDisplayed: 4/5/2024 23:25